Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MDRNA signs licensing agreement with Roche
Michael French, president and CEO of MDRNA, said: “We are pleased to have Roche recognize the value of our drug discovery platform. To have a portion of our
Michael French, president and CEO of MDRNA, said: “We are pleased to have Roche recognize the value of our drug discovery platform. To have a portion of our
The offering is expected to close on or about February 19, 2009, subject to customary closing conditions. All of the shares are being sold by the company. UBS
Combined with Gene Logic’s platforms for fine mapping and individual SNP detection, the Illumina iScan system further extends Gene Logic’s industry-leading genotyping and gene expression profiling capabilities. “Gene
The Phase IIa multicenter, double-blind, placebo-controlled study will enroll 150 pre-diabetic patients with impaired glucose tolerance, mild obesity and mild to moderate hypertension. All patients enrolled in the
This alliance sets the foundation for a clinical research project which will be conducted in Germany and in Canada under the direction of Andreas Pfutzner, who is the
The special protocol assessment (SPA) is a written agreement between the company, as the trial’s sponsor, and the FDA regarding the design, endpoints, and planned statistical analysis approach
Teva Parenteral Medicines’s (TPM) notice letter advised that it is seeking FDA approval to market daptomycin for injection prior to the expiration of two US patents, which expire
Under the agreement, Cumberland Emerging Technologies (CET) is providing formulation, grant funding, regulatory and product development assistance in exchange for rights to commercialize the new technology. The joint
The study, funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, will be conducted by investigators at the Center
The first collaboration, with Harvard University, is based upon a new pain-drug-delivery technique that targets pain-sensing neurons without affecting motor neurons. Under the terms of the agreement, Endo